Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.
Khan A et al.
Scientific Reports, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.
Molica S et al.
Cancers, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Blombery P et al.
Leukemia, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Computational insights into mutation-induced binding changes in Bruton's Tyrosine Kinase with non-covalent inhibitors.
Mallen JJ et al.
Journal of Biomolecular Structure & Dynamics, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Brown JR et al.
Blood Advances, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Gandhi V et al.
Research Square, 2025
Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node.
Xia Y et al.
Frontiers in Immunology, 2025
Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View.
Molica S et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2025
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.
Arcari A et al.
Cancers, 2024
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Biorxiv : the Preprint Server for Biology, 2024
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies.
Bravo-Gonzalez A et al.
Cancers, 2024
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
Song PR et al.
Acta Pharmacologica Sinica, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA et al.
Blood, 2024
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Wong RL et al.
Leukemia, 2024
New Means and Challenges in the Targeting of BTK.
Nawaratne V et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C et al.
Blood Advances, 2024
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K et al.
International Journal of Molecular Sciences, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S et al.
Science (new York, N.y.), 2024
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.
Schmid VK et al.
Frontiers in Oncology, 2024
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A et al.
Genes, 2023
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Qi J et al.
Blood Advances, 2023
Case report: Synergistic defects of CASP10 and BTK leading to autoimmune lymphoproliferative syndrome type IIa, complicated by severe hemophagocytic lymphohistiocytosis.
Zhang W et al.
Immunologic Research, 2023
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA et al.
Blood Advances, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Structural Complementarity of Bruton's Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases.
Najmi A et al.
Pharmaceuticals (basel, Switzerland), 2023
Real-world management of targeted therapies in chronic lymphocytic leukemia.
Weis TM et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2022
On-Target BTK Mutations Promote Resistance to Noncovalent BTK Inhibitors.
Unknown Author
Cancer Discovery, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E et al.
The New England Journal of Medicine, 2022
The potential of pirtobrutinib in multiple B-cell malignancies.
Jensen JL et al.
Therapeutic Advances in Hematology, 2022